Propanc Biopharma, Inc. (PPCB) is a leading oncology player dedicated to developing innovative cancer treatments for patients afflicted with pancreatic, ovarian, and colorectal cancers. By leveraging over a century's worth of scientific research on enzyme use, Propanc Biopharma has pioneered a novel therapeutic approach.

Unlike many approved cancer treatments, Propanc Biopharma's products exert multiple effects on cancerous cells, inhibiting tumor growth and potentially preventing metastasis. Encouraging results from scientific research and patient treatments in the UK and Australia have provided evidence of the effectiveness of their treatment, prompting the need for further development. Propanc Biopharma is focused on building a substantial intellectual property portfolio that encompasses new formulations, administration routes, and therapeutic targets.

They are determined to meet the increasing demand for easy-to-administer cancer treatments, as cancer remains the leading cause of death worldwide. Driven by strong partnerships and an international network of research and development collaborations, Propanc Biopharma is positioned to excel in the field of cancer therapy. With a robust intellectual property portfolio and a dedicated leadership team, they are committed to advancing the future of cancer treatment